BBO-8520 Receives FDA Fast Track Designation for KRASG12C-Mutated NSCLC
核心洞察
The FDA has granted Fast Track designation to BBO-8520 for treating KRASG12C-mutated metastatic non-small cell lung cancer (搜索) (NSCLC (搜索)).
BBO-8520 is an investigational oral therapy designed to inhibit both the active and inactive states of KRASG12C (搜索).
The Fast Track designation aims to expedite the development and review of BBO-8520, addressing an unmet need in NSCLC (搜索) treatment.
BridgeBio Oncology Therapeutics (搜索)' BBO-8520, an investigational oral therapy, has received Fast Track designation from the FDA for the treatment of adult patients with previously treated KRASG12C-mutated metastatic non-small cell lung cancer (搜索) (NSCLC (搜索)). This designation is intended to accelerate the development and review process for drugs addressing unmet medical needs in serious conditions.
BBO-8520 is designed to inhibit both the active ("ON") and inactive ("OFF") states of the KRASG12C (搜索) protein, a mechanism intended to overcome resistance to existing therapies. Preclinical models have demonstrated that BBO-8520 effectively inhibits tumor growth, even in cases where resistance to sotorasib (Lumakras) has developed.
ONKORAS-101 Phase 1 Trial
Currently, BBO-8520 is being evaluated in the Phase 1 ONKORAS-101 trial (NCT06343402), a first-in-human, open-label, multicenter study. This trial aims to assess the safety, tolerability, and pharmacokinetics of BBO-8520 as a single agent and in combination with pembrolizumab (Keytruda) in patients with KRASG12C (搜索)-mutated NSCLC (搜索) and colorectal cancer (搜索). The trial includes a dose escalation phase (cohorts 1a and 1b) and a dose expansion phase (cohorts 2a and 2b).
Patients enrolled in the trial have histologically documented locally advanced or metastatic KRASG12C (搜索)-mutated NSCLC (搜索), measurable disease by RECIST v1.1, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Exclusion criteria include malignancy within the last 2 years, untreated brain metastases, and known hypersensitivity to BBO-8520 or its excipients. For cohorts 2a and 2b, additional exclusion criteria include known hypersensitivity to pembrolizumab, active autoimmune disease, or a history of interstitial lung disease or pneumonitis.
The primary endpoints of the study are the incidence and severity of treatment-emergent adverse events (AEs) and serious AEs, as well as dose-limiting toxicities. Secondary endpoints include progression-free survival, duration of response, overall survival, and pharmacokinetics of BBO-8520, including Cmax, time to Cmax, and half-life.
Industry Perspective
"Receiving fast track designation for BBO-8520 is a significant milestone in our efforts to overcome the limitations of existing therapies for KRASG12C (搜索)-mutant cancers," said Yong Ben, MD, chief medical and development officer of BridgeBio Oncology Therapeutics (搜索). "BBO-8520 represents a first-in-class approach with potential to address high unmet medical needs and shift the paradigm for cancer treatment."
The first patients were dosed with BBO-8520 in June 2024, and the estimated primary completion date for the study is August 2027.